Neurizon Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Neurizon Therapeutics zal naar verwachting zijn omzet verhogen met 58.2% per jaar.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Pharmaceuticals winstgroei	21.4%
Inkomstengroei	58.2%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	01 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

DB:ECQ0 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2027	207	N/A	N/A	-7	1
6/30/2026	N/A	N/A	N/A	-9	1
6/30/2025	N/A	N/A	N/A	-8	1
6/30/2024	1	-9	-5	-5	N/A
3/31/2024	1	-6	-3	-3	N/A
12/31/2023	4	-8	-2	-2	N/A
9/30/2023	4	-7	-2	-2	N/A
6/30/2023	1	-2	-2	-2	N/A
3/31/2023	2	-1	-1	-1	N/A
12/31/2022	4	-1	0	0	N/A
9/30/2022	4	-1	-1	-1	N/A
6/30/2022	5	-2	-1	-1	N/A
3/31/2022	4	-2	-1	-1	N/A
12/31/2021	4	-2	-2	-1	N/A
9/30/2021	4	-2	-1	-1	N/A
6/30/2021	4	-1	-1	-1	N/A
3/31/2021	4	-2	-1	-1	N/A
12/31/2020	3	-2	0	0	N/A
9/30/2020	4	-2	-1	-1	N/A
6/30/2020	4	-1	-1	-1	N/A
3/31/2020	4	-2	-2	-2	N/A
12/31/2019	4	-2	-2	-2	N/A
9/30/2019	4	-2	-2	-2	N/A
6/30/2019	4	-2	-2	-2	N/A
3/31/2019	4	-1	-2	-1	N/A
12/31/2018	4	-1	-2	-1	N/A
9/30/2018	4	-2	-2	-1	N/A
6/30/2018	3	-3	-2	-2	N/A
3/31/2018	3	-2	N/A	-2	N/A
12/31/2017	3	-2	N/A	-2	N/A
9/30/2017	3	-2	N/A	-1	N/A
6/30/2017	3	-1	N/A	-1	N/A
3/31/2017	3	-2	N/A	-1	N/A
12/31/2016	3	-3	N/A	-1	N/A
9/30/2016	3	-4	N/A	-1	N/A
6/30/2016	3	-4	N/A	-2	N/A
3/31/2016	3	-3	N/A	-2	N/A
12/31/2015	3	-2	N/A	-2	N/A
9/30/2015	3	-2	N/A	-2	N/A
6/30/2015	2	-2	N/A	-2	N/A
3/31/2015	2	-2	N/A	-2	N/A
12/31/2014	2	-2	N/A	-1	N/A
9/30/2014	2	-2	N/A	-1	N/A
6/30/2014	2	-1	N/A	-2	N/A
12/31/2013	2	-1	N/A	-1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van ECQ0 boven de spaarquote ( 1% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van ECQ0 naar verwachting sneller zal groeien dan de markt German

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van ECQ0 naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er wordt verwacht dat ECQ0 volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat ECQ0 volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ECQ0 naar verwachting over 3 jaar hoog zal zijn

Neurizon Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

PharmAust Limited, Annual General Meeting, Sep 30, 2024

PharmAust Limited has filed a Follow-on Equity Offering.

PharmAust Limited has completed a Follow-on Equity Offering in the amount of AUD 3.459 million.

PharmAust Limited has announced a Derivatives Offering in the amount of AUD 39.612456 million.

PharmAust Limited, Annual General Meeting, Nov 20, 2023

Full year 2023 earnings released: AU$0.019 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

PharmAust Limited Announces Executive Changes

PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023

First half 2023 earnings released: EPS: AU$0 (vs AU$0.004 loss in 1H 2022)

PharmAust Limited Progresses to Elevated Doses in MND Patients

PharmAust Limited Completes First Cohort of Six Patients in Its Phase 1/2 Clinical Trial of Lead Drug Candidate Monepantel in Motor Neurone Disease/Amyotrophic Lateral Sclerosis

PharmAust Limited Announces MND Trial Completes Enrolment of First Patient Cohort

No independent directors

PharmAust Limited, Annual General Meeting, Nov 10, 2022

PharmAust Limited Recruits First Pet Dog with B Cell Lymphoma in US Canine Phase 2 Trial Assessing the Efficacy of Monepantel Treatment

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.004 loss in FY 2021)

Pharmaust Updates on Canine Cancer Trials

PharmAust Limited Announces Resignation of Richard Mollard as Chief Scientific Officer

Pharmaust Limited Announces Arrival of Mpl Tablets in Melbourne for Motor Neuron Disease Clinical Trial

PharmAust Limited Expands Lymphoma Canine Trial to the USA

No independent directors

PharmAust Limited Announces Preliminary MPL Anti-Viral Leukaemia Preclinical WEHI Results

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

First half 2022 earnings: Revenues and EPS in line with analyst expectations

PharmAust Limited Provides Update on Manufacture of MPL & Tablets for Clinical Trials

Full year 2021 earnings released: AU$0.004 loss per share (vs AU$0.005 loss in FY 2020)

Pharmaust Limited Achieves Phase IIB Dog Trial's Interim Clinical Endpoints

PharmAust Receives Ethics Approval for Phase I Trial of Monepantel in Motor Neurone Disease

PharmAust Limited Announces Phase IIb Canine Trial Identifies Therapeutic Window for MPL

PharmAust Ltd Provides an Update on Phase IIb Trial Testing the Effects of Monepantel Upon Pet Owners' Dogs with Treatment Naïve B Cell Lymphoma

PharmAust Limited Announces Monepantel COVID-19 Testing in the Netherlands

PharmAust and Leiden University Medical Centre Provide Update on Monepantel COVID-19 Testing

PharmAust and Olivia Newton-John Cancer Research Institute to Continue MPL Pre-clinical Investigations

PharmAust Ltd to Commence Phase IIb Dog Cancer Trial

PharmAust Limited Provides an Update on Analysis at the Olivia Newton-John Cancer Research Institute Investigating the Mechanism of Action of Monepantel Upon Cancer Cells

Pharmaust Ltd, Entered into A Service Agreement with Leiden University Medical Center (Lumc) in Netherlands for Lumc to Test

Full year earnings released - €0.0046 loss per share

Full year earnings released - €0.0046 loss per share

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven